AKRO - Corcept's Phase 3 Trial And Other News: The Good Bad And Ugly Of Biopharma
Corcept Therapeutics Starts Phase 3 Pancreatic Cancer Trial
Corcept Therapeutics Inc. (CORT) announced enrollment of the first participant in its Phase 3 trial RELIANT. The trial seeks to evaluate relacorilant in conjunction with nab-paclitaxel for treating patients with metastatic pancreatic cancer. The company seeks to enroll 80 patients suffering from metastatic pancreatic cancer. The data collated from 40 of these patients will be used for carrying out interim analysis.
During the trial, each patient will be administered relacorilant plus nab-paclitaxel. The primary endpoint for the trial is Objective Response Rate, while secondary endpoints